共 88 条
[1]
Hofman MS(2020)Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study Lancet 395 1208-1216
[2]
Lawrentschuk N(2021)Performance of [(68)Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients Eur J Nucl Med Mol Imaging 48 2925-2934
[3]
Francis RJ(1995)Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues Urol Oncol 1 18-28
[4]
Tang C(1997)Prostate-specific membrane antigen expression in normal and malignant human tissues Clin Cancer Res 3 81-85
[5]
Vela I(1998)Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases Urology 52 637-640
[6]
Thomas P(2020)Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis Eur Urol 77 403-417
[7]
Afshar-Oromieh A(2019)Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] BMC Cancer 19 18-688
[8]
da Cunha ML(2017)F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients Eur J Nucl Med Mol Imaging 44 678-51
[9]
Wagner J(2022)Recent advancements in (18)F-labeled PSMA targeting PET radiopharmaceuticals Nucl Med Biol 106–107 29-2076
[10]
Haberkorn U(2019)Radiohybrid ligands: a novel tracer concept exemplified by (18)F- or (68)Ga-labeled rhPSMA-inhibitors J Nucl Med 49 2064-4747